- Perrigo Company plc recently completed a major shift in the Russell index family, moving from the Russell 1000 and Midcap indices into several Russell 2000 benchmarks, while the Board added consumer-products veterans Salman Amin and Omer Gajial as independent directors on June 30, 2026.
- The combination of index reclassification and fresh board expertise in consumer health, retail, and e-commerce could influence how investors assess Perrigo’s scale, peer group, and strategic direction.
- Next, we’ll examine how Perrigo’s move into Russell 2000 indices may affect its existing investment narrative around OTC and infant nutrition.
Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Perrigo Investment Narrative Recap
To own Perrigo, you generally need to believe its over the counter and infant nutrition franchises can translate into durable, cash generative brands despite recent losses and slow category growth. The Russell shift itself does not materially change that fundamental thesis, but it may affect near term trading and liquidity around the key catalyst of stabilizing OTC and formula volumes. The biggest risk remains weak category demand and share pressure in infant formula and core self care products.
The most relevant development alongside the index changes is the appointment of Salman Amin and Omer Gajial to the board. Their backgrounds in consumer products, retail, and e commerce add experience that connects directly to Perrigo’s reliance on store brand partnerships and OTC brand building, both central to any recovery in revenue and margins. How effectively this refreshed governance supports execution on the OTC and infant formula story will be important to watch.
But while the board refresh may help, investors should be aware that persistent category softness and share pressure in infant formula could still...
Read the full narrative on Perrigo (it's free!)
Perrigo's narrative projects $4.2 billion revenue and $73.4 million earnings by 2029. This requires fairly flat yearly revenue and an earnings increase of about $1.9 billion from -$1.8 billion today.
Uncover how Perrigo's forecasts yield a $16.50 fair value, a 47% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming Perrigo could move from a US$1.8 billion loss to about US$95 million in earnings, yet this latest index shift and leadership change may cause you to revisit whether that kind of margin turnaround still feels realistic or if the risks around weak organic growth and retailer dependence deserve more weight.
Explore 3 other fair value estimates on Perrigo - why the stock might be worth over 3x more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Perrigo research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Perrigo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perrigo's overall financial health at a glance.
No Opportunity In Perrigo?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com